Home Overview Press Room Blog Publications For Students about us
Search

Biotech & Pharma : Displaying 11-20 of 2236


Will creating monkeys with autism-like symptoms be any use?by Sam WongNew ScientistJanuary 25th, 2016Researchers are divided on whether a condition like autism can be meaningfully reproduced in monkeys.
The Battle Over CRISPR Could Make Or Break Some Biotech Companies[cites CGS' Marcy Darnovsky]by Farai ChideyaFiveThirtyEightJanuary 25th, 2016CRISPR is caught up in public offerings and a patent dispute. If used to "edit" heritable traits, it could lead us into a world of genetic haves and have-nots.
Could DTC Genome Testing Exacerbate Research Inequities?by Christine Aicardi, Maria Damjanovicova, Lorenzo Del Savio, Federica Lucivero, Maru Mormina, Maartje Niezen & Barbara PrainsackThe Hastings Center ReportJanuary 20th, 2016The expansion of 23andMe’s database as a resource for genetic science may aggravate existing biases in disease research, leading to impoverished knowledge and exacerbated inequalities.
End of the 'Test Tube Baby' as New Technique Allows IVF Fertilisation in Wombby Sarah KnaptonThe Telegraph [UK]January 19th, 2016The technique involves placing egg and sperm cells into a tiny silicone capsule and inserting it into the womb.
The Secret Lives of Egg Donors: The Strange Hell Women Go Through to Donate Their Eggsby Colette ShadeVICE BroadlyJanuary 17th, 2016We Are Egg Donors serves as an online repository of stories about the strange hell women put themselves through to receive that lump sum.
Creativity Week: Playing God with CRISPR[cites CGS' Elliot Hosman]by Aubrey SandersBreakThru RadioJanuary 16th, 2016Elliot Hosman discusses one of the most profoundly consequential debates modern science has ever faced.
CRISPR Patent War: Billions at Stake for UC Berkeleyby Lindsey HoshawKQEDJanuary 15th, 2016Whoever gets the patent will set the terms for how the technology is used.
Plug Pulled on Cancer Clinical Trial: Sudden End for $18 Million Push by California Stem Cell Agency by David JensenCalifornia Stem Cell ReportJanuary 14th, 2016California’s ambitious effort to develop a stem cell therapy for a deadly form of skin cancer collapsed abruptly last week, apparently the victim of “excessively long development timelines."
Why Is Editas Going Public? by Pete ShanksBiopolitical TimesJanuary 14th, 2016Editas, the gene-editing company founded by several of the scientists who developed CRISPR technology, announced on January 4th that it had filed preliminary paperwork for a public offering of stock.
'Spermbots' Could Help Women Trying to Conceive (includes video)Phys.orgJanuary 13th, 2016In an attempt to improve fertility, scientists have developed motorized "spermbots" that can deliver poor swimmers—that are otherwise healthy—to an egg.
Displaying 11-20 of 2236  
< Prev  Next >> 
« First Page Last Page » 
« Show Complete List » 


ESPAÑOL | PORTUGUÊS | Русский

home | overview | blog | publications| about us | donate | newsletter | press room | privacy policy

CGS • 1122 University Ave, Suite 100, Berkeley, CA 94702 • • (p) 1.510.665.7760 • (F) 1.510.665.8760